title: [Long-term results of transtympanic gentamicin treatment in Meniere's disease].
abstract: OBJECTIVE
  To determine the long-term hearing and vestibular outcomes in patients with intractable vertigo caused by unilateral Meniere's disease, who were treated with transtympanic injection of gentamicin.
  
  
  METHODS
  the study was a long-term analysis of hearing and control of vertigo in patients with unilateral Meniere's disease who received transtympanic gentamicin.
  
  
  METHODS
  Pure-tone thresholds and ENG, along with the control of vertigo. Criteria described in 1995 by the American Academy of Otolaryngology - Head and Neck Surgery were used. Patients treated with transtympanic gentamicin had definite Meniere's disease and had intractable vertigo despite optimal medical therapy, no symptoms suggestive of Meniere's disease in the contralateral ear, and serviceable hearing in the contralateral ear. The study analyzed the outcomes of 9 patients for whom follow-up data were available for periods greater than 24 months after transtympanic gentamicin.
  
  
  RESULTS
  Complete control of vertigo was obtained in all 9 patients. Profound sensorineural hearing loss occurred only in 1 patient. Hearing was improved in 6 patients, and in 2 was unchanged.
  
  
  CONCLUSIONS
  Transtympanic gentamicin therapy is a good method of controlling vertigo and the risk of hearing loss is low.
authors.affiliation: Klinika Otolaryngologii AM w Warszawie.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Pierchała
authors.forename: Irena
authors.initials: I
authors.lastname: Krzeska-Malinowska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kowalska
authors.forename: Robert
authors.initials: R
authors.lastname: Bartoszewicz
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Niemczyk
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects; D006309:Hearing / Q000187:drug effects*; D006801:Humans; D007267:Injections; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014432:Tympanic Membrane; D014717:Vertigo / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins